Morgan Stanley analyst David Risinger reiterated an Equalweight rating and $40.00 price target on Pfizer (NYSE: PFE) after learning that ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE